Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing angiotensin converting enzyme inhibitors, B vitamins and ginkgo biloba extracts

A technology for angiotensin and B vitamins, applied in the field of pharmacy, can solve the problems of no obvious advantage in target organ protection and insignificant curative effect, etc.

Inactive Publication Date: 2009-12-02
SHENZHEN AUSA PHARM CO LTD
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] ACEI antihypertensive drugs still have certain problems in clinical practice. First, their antihypertensive efficacy has a certain limit. A large number of literature reports have a total effective rate of only about 50% to 60%, and 40% to 50% are ineffective or have no significant curative effect.
Compared with other antihypertensive drugs, the target organ protection effect of ACEI antihypertensive drugs has no obvious advantage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing angiotensin converting enzyme inhibitors, B vitamins and ginkgo biloba extracts
  • Pharmaceutical composition containing angiotensin converting enzyme inhibitors, B vitamins and ginkgo biloba extracts
  • Pharmaceutical composition containing angiotensin converting enzyme inhibitors, B vitamins and ginkgo biloba extracts

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～10

[0085] Embodiments 1-10: Preparation of enalapril maleate / B vitamins / gingko leaves with different content ratios (1000 pieces)

[0086] The granules obtained according to the formulation shown in Table 1 were made into tablets.

[0087] Table 1 embodiment 1~10 tablet formula composition

[0088]

[0089] Preparation:

[0090] (1) Take the prescribed amount of enalapril maleate, B vitamins and ginkgo biloba extract and pass through a 100-mesh sieve respectively, and then mix them uniformly by the method of equal increments for subsequent use;

[0091] (2) After drying the other auxiliary materials at 70°C for about 2 hours, pass through a 100-mesh sieve;

[0092] (3) Get the microcrystalline cellulose, carboxymethyl starch sodium, and starch of prescription quantity and mix, and then mix uniformly with the raw material medicine that mixes by equal increment method;

[0093] (4) adding 5% povidone K-3095% ethanol solution in an appropriate amount to make a soft material, g...

Embodiment 11～20

[0095] Examples 11-20: Preparation of Enalapril Maleate / B Vitamins / Ginkgo Leaf Capsules with Different Contents and Proportions (1000 Capsules)

[0096] The granules obtained according to the formula shown in Table 2 are made into capsules.

[0097] Table 2 Embodiment 11~20 capsule formula composition

[0098]

[0099] Preparation:

[0100] (1) Take the prescribed amount of enalapril maleate, B vitamins and ginkgo biloba extract and pass through a 100-mesh sieve respectively, and then mix them uniformly by the method of equal increments for subsequent use;

[0101] (2) After drying the other auxiliary materials at 70°C for about 2 hours, pass through a 100-mesh sieve;

[0102] (3) get the microcrystalline cellulose, carboxymethyl starch sodium, lactose, starch of recipe quantity and mix evenly, then mix with the raw material medicine that mixes by equal increment method;

[0103] (4) adding 5% povidone K-30 95% ethanol solution in an appropriate amount to make a soft mat...

Embodiment 21～29

[0105] Examples 21-29: Preparation of Benazepril Hydrochloride / B Vitamins / Ginkgo Leaf with Different Contents and Proportions

[0106] The preparation method is the same as in Example 1, and the granules obtained according to the formula shown in Table 3 are made into tablets.

[0107] Table 3 embodiment 21~29 tablet formula composition

[0108]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition containing one of angiotensin converting enzyme inhibitors (ACEI) and active metabolites or medical salt thereof in medicine dosage, one or more of B vitamins in medicine dosage, ginkgo biloba extracts (GbE) in medicine dosage and a medical carrier, and relates to application of the pharmaceutical composition in preparing medicines for treating, preventing or retarding stroke. The medicines prepared by the pharmaceutical composition provided by the invention are superior to the simple antihypertensive drugs in the aspect of treating, preventing or retarding stroke and facilitate the patients to take. The invention belongs to the pharmaceutical field.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing an angiotensin-converting enzyme inhibitor in a medicinal dose, one or more of the B vitamins in a medicinal dose, a ginkgo leaf extract in a medicinal dose and a pharmaceutically acceptable carrier , and the use of the pharmaceutical composition in the preparation of medicines for preventing, treating or delaying stroke. The present invention belongs to the field of pharmacy. Background technique [0002] In my country, stroke is not only one of the main causes of death, but also the main cause of continuous disability and loss of self-care ability. This makes it more important to choose an ideal antihypertensive drug to further reduce the risk of stroke while lowering blood pressure [Fan Li, The relationship between controlling hypertension, hyperlipidemia and preventing stroke, People's Military Medical, 2004, 47(8): 479-481; Zhang Hongye et al., A Prospective Study on the Risk Factor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/16A61K45/06A61K9/00A61P9/10A61P9/12A61K31/401A61K31/4415A61K31/472A61K31/519A61K31/551A61K31/714
Inventor 田敏卿范文峰陈光亮王文艳徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com